Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 2Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1

Conditions

Lymphoma 45Breast Neoplasms 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Large B-Cell, Diffuse 41Lymphoma, Non-Hodgkin 39Multiple Myeloma 35Leukemia 34Melanoma 32Leukemia, Lymphocytic, Chronic, B-Cell 32Recurrence 31Leukemia, Myeloid, Acute 28Lymphoma, Follicular 27Lymphoma, B-Cell 25Ovarian Neoplasms 24Lymphoma, Mantle-Cell 23Neoplasm Metastasis 22Hematologic Neoplasms 19Pancreatic Neoplasms 18Myelodysplastic Syndromes 18Hodgkin Disease 18Burkitt Lymphoma 16Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Colorectal Neoplasms 12Stomach Neoplasms 11Waldenstrom Macroglobulinemia 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Carcinoma, Hepatocellular 9

Interventions

Gemcitabine 8pembrolizumab 5Paclitaxel 4Capecitabine 4Albumin-Bound Paclitaxel 4Nivolumab 3Fluorouracil 3Cyclophosphamide 3Carboplatin 3sargramostim 2poly ICLC 2fludarabine 2Prednisone 2Oxaliplatin 2Irinotecan 2Hydroxychloroquine 2Erlotinib Hydrochloride 2Dexamethasone 2Cisplatin 2130-nm albumin-bound paclitaxel 2temsirolimus 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1rucaparib 1resiquimod 1repotrectinib 1regorafenib 1pralsetinib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma × Cyclophosphamide × Clear all
NCT05922930 2026-05-06

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
51 enrolled
GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06782932 2025-12-03

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Recruiting
38 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT06532799 2024-11-12

BAH250

Essen Biotech

Phase 1/2 Recruiting
75 enrolled
Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡